Evidence map›Paper›PMID 38116005›Full record

ArticleFrontiers in immunology2023

Single-cell landscape of immune cells during the progression from HBV infection to HBV cirrhosis and HBV-associated hepatocellular carcinoma.

Qingquan Bai, Runyang Li, Xiao He, Xiaoting Hong, Ying Yan, Zhengyang Zhao, Han Lin, Frank Tacke, Cornelius Engelmann, Tianhui Hu

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. IL-18-Mediated Tumor Immune Evasion.Current issues in molecular biology · 2026
    Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. LRG1 Drives AML Progression by Disrupting Myeloid Progenitor Regulation.Blood and lymphatic cancer : targets and therapy · 2025
    Article
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 3 countries.

Qingquan BaiDepartment of Hepatology & Gastroenterology, Charité Universitätsmedizin Berlin, Berlin, Germany.
Runyang LiCancer Research Center, School of Medicine, Xiamen University, Xiamen, China.
Xiao HeDepartment of Neurology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, China.
Xiaoting HongCancer Research Center, School of Medicine, Xiamen University, Xiamen, China.
Ying YanCancer Research Center, School of Medicine, Xiamen University, Xiamen, China.
Zhengyang ZhaoCancer Research Center, School of Medicine, Xiamen University, Xiamen, China.
Han LinDepartment of Hepatic Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Frank TackeDepartment of Hepatology & Gastroenterology, Charité Universitätsmedizin Berlin, Berlin, Germany.
Cornelius EngelmannDepartment of Hepatology & Gastroenterology, Charité Universitätsmedizin Berlin, Berlin, Germany.
Tianhui HuCancer Research Center, School of Medicine, Xiamen University, Xiamen, China.
Xiamen University · CNBerlin Institute of Health at Charité - Universitätsmedizin Berlin · DECharité - Universitätsmedizin Berlin · DEHarbin Medical University · CNShandong Provincial QianFoShan Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Immune cells play crucial roles in the development of chronic hepatitis B virus (HBV) infection, leading to cirrhosis and hepatocellular carcinoma (HCC). However, their functions at different disease stages are not fully understood. Methods: In this study, we used single-cell RNA sequencing (scRNA-seq) to characterize the human liver immune microenvironment at different disease stages. We analyzed scRNA-seq data from 118,455 immune cells obtained from livers of six healthy individuals, four patients with HBV infection, five patients with HBV cirrhosis, and three patients with HBV-associated HCC. Results: Our results showed an accumulation of scar-associated macrophages during disease progression, and we identified two relevant immune subsets, Macrophage-CD9/IL18 and macrophage-CD9/IFI6. Macrophage-CD9/IL18 expanded from HBV infection to cirrhosis, while macrophage-CD9/IFI6 expanded from cirrhosis to HCC. We verified the existence of Macrophage-CD9/IFI6 using multiplex immunofluorescence staining. We also found an increase in cytotoxic NK Cell-GNLY during progression from cirrhosis to HCC. Additionally, the proportion of CD4 T cell-TNFAIP3, CD8 T cell-TNF (effector CD8 T cells), and CD8 T cell-CD53 increased, while the proportion of Treg cells decreased from HBV infection to cirrhosis. The proportion of Treg and CD8 T cell-LAG3 (Exhausted CD8 T cell) enhanced, while the proportion of CD8 T cell-TNF (effector CD8 T cells) decreased from cirrhosis to HCC. Furthermore, GSEA enrichment analyses revealed that MAPK, ERBB, and P53 signaling pathways in myeloid cells were gradually inhibited from HBV infection to cirrhosis and HCC. Discussion: Our study provides important insights into changes in the hepatic immune environment during the progression of HBV-related liver disease, which may help improve the management of HBV-infected liver diseases.

Indexed as

Carcinoma, HepatocellularHepatitis BHepatitis B, ChronicLiver NeoplasmsHepatitis B virusHumansInterleukin-18Liver CirrhosisTumor MicroenvironmentInterleukin-18cirrhosisHBV infectionhepatitis Bhepatocellular carcinomascRNA-seq

Identifiers

PMID38116005
PMCPMC10729758
OpenAlexW4389393797

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.